EUVIMEDOpdag EUVIMED
Klinische StudieMultizentrische StudieOpen access · CC BY-NC-ND 4.0

Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies

David N O'Neal iD, Adrian Sartoretto iD, Bronte A Holt, Barham K Abu Dayyeh, Rhys Vaughan iD, Georgina Cameron iD, Sujievvan Chandran iD, Alexander J Thompson iD, Howard McCollister, Paul Severson, Andrew C Storm, Lian Cunningham and 1 more

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.70533 ↗

At a glance

Klinische Studie in Diabetes, Obesity and Metabolism, 2026. Written by David N O'Neal and 12 co-authors. Institution: Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia. Major MEDLINE topics: Diabetes Mellitus, Type 2, Duodenum, Electric Stimulation Therapy. Cited 5 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aims

The duodenum plays a central role in metabolic regulation, influencing insulin sensitivity, and glucose homeostasis. In type 2 diabetes (T2D), structural and functional abnormalities of the duodenal mucosa (“diabetic duodenopathy”) are increasingly recognized as contributors to insulin resistance and dysglycaemia. Non‐thermal duodenal cellular regeneration using pulsed electric field (PEF) therapy offers a novel approach to restore metabolic signalling and target the underlying pathophysiology of T2D. Materials and methods An integrated analysis of two parallel, open‐label, multicentre feasibility studies evaluated the safety, feasibility, and metabolic effects of PEF‐based duodenal therapy in adults with uncontrolled T2D treated with non‐insulin medications. Eligible participants ( n = 71) were 18–70 years old, with body mass index 24–40 kg/m 2 and glycated haemoglobin (HbA1c) 7.5%–11.0% (58–97 mmol/mol). Participants underwent endoscopic, catheter‐based PEF therapy to the duodenal wall (600 or 750 V, single or double application) and were followed for 48 weeks. The primary endpoint was the incidence of device‐ or procedure‐related serious adverse events (SAEs).

Results

No device‐ or procedure‐related SAEs were reported, demonstrating a favourable safety profile. Higher‐energy dosing, double applications, and use of the second‐generation catheter yielded greater and sustained metabolic improvements through 48 weeks, including reductions in HbA1c, fasting glucose, weight, and markers of insulin resistance. Continuous glucose monitoring showed sustained increases in time‐in‐range and reduced glycaemic variability.

Conclusions

PEF‐based duodenal regeneration therapy was safe, technically feasible, and associated with durable metabolic improvements over 48 weeks. These findings support further evaluation of duodenal electroporation as a novel, minimally invasive approach for managing T2D.

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2DuodenumElectric Stimulation TherapyAdolescentAdultAgedFemaleHumansMaleMiddle AgedYoung AdultBlood GlucoseFeasibility StudiesGlycated HemoglobinInsulin ResistanceProof of Concept StudyTreatment Outcome

Author keywords

continuous glucose monitoring (CGM)duodenopathyendoscopyglycaemic controlpulsed electric field (PEF)type 2 diabetes (T2D)

Substances

Blood GlucoseGlycated Hemoglobinhemoglobin A1c protein, human

Authors and institutions

  • Department of Medicine, St Vincent's Hospital, University of Melbourne, Fitzroy, Victoria, Australia.
  • Department of Endocrinology and Diabetes, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Australian Centre for Accelerating Diabetes Innovations, Melbourne Medical School, The University of Melbourne, Melbourne, Victoria, Australia.
  • The BMI Clinic, Double Bay, New South Wales, Australia.
  • Department of Gastroenterology, St Vincent's Hospital, Melbourne, Victoria, Australia.
  • Division of Gastroenterology and Hepatology, Cedars-Senai Medical Center, Los Angeles, California, USA.

ORCID profiles: David N O'Neal, Adrian Sartoretto, Rhys Vaughan, Georgina Cameron, Sujievvan Chandran, Alexander J Thompson, Elif I Ekinci

Cite

APA

O'Neal, D. N., Sartoretto, A., Holt, B. A., Abu Dayyeh, B. K., Vaughan, R., Cameron, G., Chandran, S., Thompson, A. J., McCollister, H., Severson, P., Storm, A. C., Cunningham, L., & Ekinci, E. I. (2026). Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70533

Vancouver

O'Neal DN, Sartoretto A, Holt BA, Abu Dayyeh BK, Vaughan R, Cameron G, et al. Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70533

BibTeX
@article{ONeal2026,
  author = {O'Neal, David N and Sartoretto, Adrian and Holt, Bronte A and Abu Dayyeh, Barham K and Vaughan, Rhys and Cameron, Georgina and Chandran, Sujievvan and Thompson, Alexander J and McCollister, Howard and Severson, Paul and Storm, Andrew C and Cunningham, Lian and Ekinci, Elif I},
  title = {Safety, feasibility, and dose‐dependent metabolic effects of endoscopic duodenal pulsed electric field therapy in adults with type 2 diabetes: Results from two multicentre proof‐of‐concept studies},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.70533}
}
Start for free →